Literature DB >> 15550559

Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers.

Mariona Graupera1, Sandra March, Pablo Engel, Juan Rodés, Jaume Bosch, Joan-Carles García-Pagán.   

Abstract

CCl(4) cirrhotic rat liver exhibits a hyperresponse to the alpha(1)-adrenergic agonist methoxamine (Mtx) that is associated with enhanced thromboxane A(2) (TXA(2)) production and is abrogated by indomethacin. To further elucidate the molecular mechanisms involved in the hyperresponse to vasoconstrictors, portal perfusion pressure dose-response curves to Mtx were performed in CCl(4) cirrhotic rats livers after preincubation with vehicle, the cyclooxygenase (COX)-1 selective inhibitor SC-560, and the COX-2 selective inhibitor SC-236. TXA(2) production was determined in samples of the perfusate. COX-1 expression was analyzed and quantified in hepatocytes, Kupffer cells, sinusoidal endothelial cells (SEC), and hepatic stellate cells (HSC) isolated from control and cirrhotic rat livers by double-immunofluorescence staining, with specific markers for each population using flow cytometry or Western blot analysis. COX-1 protein levels were not significantly increased in cirrhotic livers, but COX-2 protein expression was increased. COX-1 inhibition, but not COX-2, significantly attenuated the response to Mtx and prevented the increased production of TXA(2). Cirrhotic livers showed an increased expression of COX-1 in SEC and reduced expression in HSC compared with control livers, whereas COX-1 was similarly distributed in Kupffer cells. Despite abundant hepatic COX-2 expression, the increased response to Mtx of cirrhotic livers is mainly dependent of COX-1. Upregulation of COX-1 in cirrhotic SEC may be responsible for the hyperesponse to Mtx.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550559     DOI: 10.1152/ajpgi.00300.2004

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  17 in total

1.  Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule.

Authors:  Sandra March; Mariona Graupera; María Rosa Sarrias; Francisco Lozano; Pilar Pizcueta; Jaume Bosch; Pablo Engel
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

3.  Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin.

Authors:  Chii-Shyan Lay; C-M-Y May; Fa-Yauh Lee; Yang-Te Tsai; Shou-Dong Lee; Shu Chien; Shlomoh Sinchon
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

Review 4.  New cellular and molecular targets for the treatment of portal hypertension.

Authors:  Jordi Gracia-Sancho; Raquel Maeso-Díaz; Anabel Fernández-Iglesias; María Navarro-Zornoza; Jaime Bosch
Journal:  Hepatol Int       Date:  2015-03-05       Impact factor: 6.047

Review 5.  Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Liver Int       Date:  2011-07-05       Impact factor: 5.828

Review 6.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

7.  The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.

Authors:  Barbara Schreier; Anja Wolf; Stefanie Hammer; Sabine Pohl; Sigrid Mildenberger; Sindy Rabe; Michael Gekle; Alexander Zipprich
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 8.  Role of liver sinusoidal endothelial cells in liver diseases.

Authors:  Jordi Gracia-Sancho; Esther Caparrós; Anabel Fernández-Iglesias; Rubén Francés
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-15       Impact factor: 46.802

Review 9.  Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Authors:  Yasuko Iwakiri; Vijay Shah; Don C Rockey
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

Review 10.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.